GBS operates as a biosensor diagnostic technology company. Co. is engaged in developing and commercializing a range of Biosensor based Point of Care ("POCT") diagnostic tests that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens and endocrinology. Co.'s principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. Co. also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. Co. operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The GBS stock yearly return is shown above.
The yearly return on the GBS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GBS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|